Yinsong Wang Selected Research

pullulan

8/2018	pH- and redox-responsive nanoparticles composed of charge-reversible pullulan-based shells and disulfide-containing poly(ß-amino ester) cores for co-delivery of a gene and chemotherapeutic agent.
1/2017	Pullulan-coated phospholipid and Pluronic F68 complex nanoparticles for carrying IR780 and paclitaxel to treat hepatocellular carcinoma by combining photothermal therapy/photodynamic therapy and chemotherapy.
3/2016	Stepwise pH-responsive nanoparticles containing charge-reversible pullulan-based shells and poly(β-amino ester)/poly(lactic-co-glycolic acid) cores as carriers of anticancer drugs for combination therapy on hepatocellular carcinoma.
4/2015	A polymeric prodrug of cisplatin based on pullulan for the targeted therapy against hepatocellular carcinoma.
10/2014	pH-sensitive pullulan-based nanoparticle carrier for adriamycin to overcome drug-resistance of cancer cells.
1/2014	Core-shell nanoparticles based on pullulan and poly(β-amino) ester for hepatoma-targeted codelivery of gene and chemotherapy agent.
9/2013	pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yinsong Wang Research Topics

Disease

22	Neoplasms (Cancer) 01/2022 - 06/2010
10	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2014
6	Neoplasm Metastasis (Metastasis) 03/2021 - 01/2017
6	Hepatocellular Carcinoma (Hepatoma) 08/2018 - 09/2013
3	Squamous Cell Carcinoma of Head and Neck 09/2020 - 06/2017
2	Periodontitis 12/2021 - 01/2021
2	Melanoma (Melanoma, Malignant) 03/2021 - 01/2017
2	Rupture 08/2018 - 01/2018
1	Triple Negative Breast Neoplasms 11/2021
1	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2019
1	Brain Injuries (Brain Injury) 01/2019
1	Brain Neoplasms (Brain Tumor) 12/2018
1	Body Weight (Weight, Body) 01/2017
1	Carcinoma (Carcinomatosis) 03/2015

Drug/Important Bio-Agent (IBA)

7	Pharmaceutical PreparationsIBA 11/2019 - 06/2010
7	pullulanIBA 08/2018 - 09/2013
6	1-phenyl-3,3-dimethyltriazene (PDT)IBA 12/2021 - 01/2017
6	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2019 - 01/2014
5	EstersIBA 10/2019 - 01/2014
4	Peptides (Polypeptides)IBA 01/2022 - 06/2017
4	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 03/2021 - 01/2017
4	AcidsIBA 11/2020 - 03/2015
3	Celecoxib (Celebrex)FDA Link 11/2019 - 01/2017
3	DisulfidesIBA 10/2019 - 08/2018
2	Polysaccharides (Glycans)IBA 01/2022 - 11/2019
2	Biocompatible Materials (Biomaterials)IBA 01/2022 - 12/2018
2	CopperIBA 01/2022 - 01/2019
2	Chelating AgentsIBA 01/2022 - 01/2019
2	Photosensitizing Agents (Photosensitizers)IBA 12/2021 - 01/2021
2	Proteins (Proteins, Gene)FDA Link 10/2020 - 02/2014
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 11/2019 - 01/2017
2	AntigensIBA 01/2019 - 11/2013
2	Drug CarriersIBA 12/2018 - 09/2013
2	ProdrugsIBA 09/2018 - 04/2015
2	DNA (Deoxyribonucleic Acid)IBA 08/2018 - 03/2015
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2017 - 03/2016
2	fosbretabulin (combretastatin A4)IBA 03/2016 - 09/2013
2	ChitosanIBA 03/2015 - 01/2014
1	DiterpenesIBA 01/2022
1	N-end cysteine peptide tumor-homing peptideIBA 01/2022
1	oridoninIBA 01/2022
1	Nanoparticle Drug Delivery SystemIBA 01/2022
1	Silicon Dioxide (Silica)FDA LinkGeneric 11/2021
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2021
1	Oxygen (Dioxygen)IBA 01/2021
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 11/2020
1	IminesIBA 11/2020
1	Neoplasm Antigens (Tumor Antigens)IBA 11/2020
1	cupric sulfide (CuS)IBA 11/2020
1	Molecular Probes (Molecular Probe)IBA 10/2020
1	IronIBA 09/2020
1	Ferrochelatase (Heme Synthetase)IBA 09/2020
1	Heme (Haem)IBA 09/2020
1	protoporphyrin IXIBA 09/2020
1	Emodin (Archin)IBA 11/2019
1	Telomerase (Telomerase Reverse Transcriptase)IBA 11/2019
1	BIBR 1532IBA 11/2019
1	resiquimodIBA 01/2019
1	Prostaglandins AIBA 01/2019
1	FluorocarbonsIBA 12/2018
1	Surface-Active Agents (Surfactants)IBA 12/2018
1	Reactive Oxygen Species (Oxygen Radicals)IBA 09/2018
1	AmidesIBA 08/2018
1	ammonium bicarbonateIBA 01/2018
1	polyhistidineIBA 01/2018
1	HydrazonesIBA 01/2018
1	HN-1 peptideIBA 06/2017
1	Protein Kinase CIBA 01/2017
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2017
1	VimentinIBA 01/2017
1	Cadherins (E-Cadherin)IBA 01/2017
1	Poloxamer (Poloxamer 407)IBA 01/2017
1	Actin Depolymerizing Factors (Cofilins)IBA 01/2017
1	Hyaluronic Acid (Hyaluronan)IBA 10/2016
1	IodineIBA 10/2016
1	Polylactic Acid-Polyglycolic Acid CopolymerIBA 03/2016
1	Cisplatin (Platino)FDA LinkGeneric 04/2015
1	Therapeutic UsesIBA 04/2015
1	graphene oxideIBA 03/2015
1	Lactose FDA LinkGeneric 03/2015
1	GraphiteIBA 03/2015
1	Fluorescein (Funduscein)FDA LinkGeneric 03/2015
1	Ammonium CompoundsIBA 03/2015
1	OxidesIBA 03/2015
1	OligosaccharidesIBA 03/2015
1	Folic Acid (Vitamin M)FDA LinkGeneric 09/2014
1	Stimuli Responsive PolymersIBA 09/2014
1	HematoporphyrinsIBA 03/2014

Therapy/Procedure

11	Therapeutics 01/2022 - 09/2013
10	Drug Therapy (Chemotherapy) 11/2019 - 01/2014
7	Photochemotherapy (Photodynamic Therapy) 12/2021 - 01/2017
7	Lasers (Laser) 11/2021 - 01/2017
4	Intravenous Injections 01/2019 - 09/2013
2	Immunotherapy 11/2020 - 01/2018
2	Photothermal Therapy 01/2017 - 10/2016
1	Chinese Traditional Medicine (Traditional Chinese Medicine) 01/2022
1	Ligation 12/2021
1	Intravenous Infusions 01/2019
1	Microspheres (Microsphere) 09/2014
1	Intravenous Administration 03/2014